LPL Financial LLC Buys 50,565 Shares of ADMA Biologics Inc $ADMA

Key Points

• LPL Financial LLC increased its stake in ADMA Biologics Inc by 84.7%, holding 110,253 shares valued at approximately $2.19 million as of its latest SEC filing.
• ADMA Biologics reported earnings of $0.15 per share, exceeding estimates, along with a revenue of $121.98 million for the last quarter, which represents a 13.8% year-over-year increase.
• Wall Street analysts have mixed ratings on ADMA shares, with one upgrade to a "strong-buy" rating and a consensus target price of $27.67, indicating potential for growth despite recent insider selling activities.

LPL Financial LLC boosted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 84.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,253 shares of the biotechnology company's stock after buying an additional 50,565 shares during the quarter. LPL Financial LLC's holdings in ADMA Biologics were worth $2,187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of ADMA. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $35,000. Tsfg LLC bought a new stake in ADMA Biologics in the first quarter worth $51,000. Farther Finance Advisors LLC boosted its position in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares during the period. GF Fund Management CO. LTD. purchased a new stake in ADMA Biologics during the fourth quarter valued at about $85,000. Finally, GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 251.6% during the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after buying an additional 4,715 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ADMA. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $27.67.

ADMA Biologics Trading Up 4.1%

Shares of ADMA Biologics stock traded up $0.70 during midday trading on Friday, reaching $17.80. 2,342,671 shares of the company's stock traded hands, compared to its average volume of 3,398,071. The stock has a 50 day moving average of $17.91 and a 200-day moving average of $18.90. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The company has a market cap of $4.25 billion, a PE ratio of 20.70 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the previous year, the firm earned $0.13 EPS. The company's quarterly revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 455,621 shares of company stock worth $9,461,633. Company insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.